



Rachel Sher
Vice President, Policy and Regulatory Affairs

Rachel Sher joins NORD as Vice President of Regulatory and Government Affairs, based in the Washington, D.C. office. Rachel brings nearly 20 years of experience in health policy and regulatory affairs, most recently serving as Deputy General Counsel at the Association for Accessible Medicines (AAM). Prior to joining AAM, Rachel served as Senior Policy Analyst in the Commissioner’s Office of Policy at the Food and Drug Administration (FDA) where she acted as the FDA lead in the 21st Century Cures Act legislative process.

For ten years before joining FDA, Rachel served as Senior FDA Counsel for Ranking Member (Formerly Chairman) Henry A. Waxman, both on the Democratic Committee Staff for the Energy and Commerce Committee and in Representative Waxman’s personal office. She holds degrees from the University of Florida Levin College of Law (J.D.), The George Washington University School of Public Health (M.P.H.) and Duke University (B.A.). Rachel brings this breadth of expertise to leading NORD’s strategy for engaging with federal and state regulatory agencies and key policymakers and effecting change for the rare disease community.

1779 MASSACHUSETTS AVENUE NW, SUITE 500
WASHINGTON, DC 20036
T 202-588-5700 ■ F 202-588-5701

55 KENOSIA AVENUE
DANBURY, CT 06810
T 203-744-0100 ■ F 203-263-9938

1900 CROWN COLONY DRIVE, SUITE 310
QUINCY, MA 02169
T 617-249-7300 ■ F 617-249-7301

rarediseases.org ■ orphan@rarediseases.org

NORD® and icon are registered trademarks of the National Organization for Rare Disorders. NORD is a registered 501(c)(3) charity organization.